{"title":"在缺血性心脏病背景下急性和慢性心力衰竭的当前管理综述","authors":"P. F. Brown, J. Thambyrajah","doi":"10.1002/cce2.50","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Heart failure secondary to left ventricular systolic dysfunction is a prevalent condition across Europe with ischemic heart disease the most common etiology. Acute heart failure is a medical emergency and management comprises diuretics and vasodilators. Several alternative intravenous treatments have been trialed in recent years but no mortality benefit has been found with these agents. For chronic heart failure there are several well-characterized disease-modifying treatments available which include beta blockers, ACE inhibitors, mineralocorticoid antagonists, and device therapy. Sacubitril/valsartan is a novel therapy that has recently been demonstrated to have additional prognostic benefit.</p>\n </section>\n \n <section>\n \n <p><b>Answer questions and earn CME:</b> https://wileyhealthlearning.com/Activity2/5222693/Activity.aspx</p>\n </section>\n </div>","PeriodicalId":100331,"journal":{"name":"Continuing Cardiology Education","volume":"3 1","pages":"30-36"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cce2.50","citationCount":"0","resultStr":"{\"title\":\"A review of the current management of acute and chronic heart failure in the context of ischemic heart disease\",\"authors\":\"P. F. Brown, J. Thambyrajah\",\"doi\":\"10.1002/cce2.50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <p>Heart failure secondary to left ventricular systolic dysfunction is a prevalent condition across Europe with ischemic heart disease the most common etiology. Acute heart failure is a medical emergency and management comprises diuretics and vasodilators. Several alternative intravenous treatments have been trialed in recent years but no mortality benefit has been found with these agents. For chronic heart failure there are several well-characterized disease-modifying treatments available which include beta blockers, ACE inhibitors, mineralocorticoid antagonists, and device therapy. Sacubitril/valsartan is a novel therapy that has recently been demonstrated to have additional prognostic benefit.</p>\\n </section>\\n \\n <section>\\n \\n <p><b>Answer questions and earn CME:</b> https://wileyhealthlearning.com/Activity2/5222693/Activity.aspx</p>\\n </section>\\n </div>\",\"PeriodicalId\":100331,\"journal\":{\"name\":\"Continuing Cardiology Education\",\"volume\":\"3 1\",\"pages\":\"30-36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-03-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/cce2.50\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Continuing Cardiology Education\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cce2.50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Continuing Cardiology Education","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cce2.50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A review of the current management of acute and chronic heart failure in the context of ischemic heart disease
Heart failure secondary to left ventricular systolic dysfunction is a prevalent condition across Europe with ischemic heart disease the most common etiology. Acute heart failure is a medical emergency and management comprises diuretics and vasodilators. Several alternative intravenous treatments have been trialed in recent years but no mortality benefit has been found with these agents. For chronic heart failure there are several well-characterized disease-modifying treatments available which include beta blockers, ACE inhibitors, mineralocorticoid antagonists, and device therapy. Sacubitril/valsartan is a novel therapy that has recently been demonstrated to have additional prognostic benefit.
Answer questions and earn CME: https://wileyhealthlearning.com/Activity2/5222693/Activity.aspx